Literature DB >> 16723565

Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.

Tatiana Bogdanovich1, Catherine Clark, Lois Ednie, Gengrong Lin, Kathy Smith, Stuart Shapiro, Peter C Appelbaum.   

Abstract

Ceftobiprole, a broad-spectrum pyrrolidinone-3-ylidenemethyl cephem currently in phase III clinical trials, had MICs between 0.008 microg/ml and 8.0 microg/ml for 321 clinical isolates of Haemophilus influenzae and between < or =0.004 microg/ml and 1.0 microg/ml for 49 clinical isolates of Moraxella catarrhalis. Ceftobiprole MIC(50) and MIC(90) values for H. influenzae were 0.06 microg/ml and 0.25 microg/ml for beta-lactamase-positive strains (n = 262), 0.03 microg/ml and 0.25 microg/ml for beta-lactamase-negative strains (n = 40), and 0.5 microg/ml and 2.0 microg/ml for beta-lactamase-negative ampicillin-resistant strains (n = 19), respectively. Ceftobiprole MIC(50) and MIC(90) values for beta-lactamase-positive M. catarrhalis strains (n = 40) were 0.12 microg/ml and 0.5 microg/ml, respectively, whereas the ceftobiprole MIC range for beta-lactamase-negative M. catarrhalis strains (n = 9) was < or =0.004 to 0.03 microg/ml. Ceftriaxone MICs usually were generally at least twofold lower than those of ceftobiprole, whereas amoxicillin-clavulanate MICs usually were higher than those of ceftobiprole. Azithromycin and telithromycin had unimodal MIC distributions against H. influenzae, with MIC(90) values of azithromycin and telithromycin of 2 microg/ml and 4 microg/ml, respectively. Except for selected quinolone-nonsusceptible H. influenzae strains, moxifloxacin proved highly active, with MIC(90) values of 0.12 microg/ml. Time-kill analyses showed that ceftobiprole, ceftriaxone, cefpodoxime, amoxicillin-clavulanate, azithromycin, telithromycin, and moxifloxacin were bactericidal at 2x MIC by 24 h against all 10 H. influenzae strains surveyed. Only modest increases in MICs were found for H. influenzae or M. catarrhalis clones after 50 serial passages in the presence of subinhibitory concentrations of ceftobiprole, and single-passage selection showed that the selection frequency of H. influenzae or M. catarrhalis clones with elevated ceftobiprole MICs is quite low.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723565      PMCID: PMC1479120          DOI: 10.1128/AAC.00044-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

Review 1.  Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.

Authors:  M R Jacobs
Journal:  Clin Microbiol Infect       Date:  2001-11       Impact factor: 8.067

2.  Antimicrobial surveillance of Haemophilus influenzae in the United States during 2000-2001 leads to detection of clonal dissemination of a beta-lactamase-negative and ampicillin-resistant strain.

Authors:  James A Karlowsky; Ian A Critchley; Renée S Blosser-Middleton; Elena A Karginova; Mark E Jones; Clyde Thornsberry; Daniel F Sahm
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

3.  Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.

Authors:  Clyde Thornsberry; Daniel F Sahm; Laurie J Kelly; Ian A Critchley; Mark E Jones; Alan T Evangelista; James A Karlowsky
Journal:  Clin Infect Dis       Date:  2002-03-01       Impact factor: 9.079

4.  Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  T A Davies; L M Kelly; D B Hoellman; L M Ednie; C L Clark; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci.

Authors:  P Hebeisen; I Heinze-Krauss; P Angehrn; P Hohl; M G Page; R L Then
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

6.  Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents.

Authors:  K L Credito; G Lin; G A Pankuch; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media.

Authors:  R Dagan; C E Johnson; S McLinn; N Abughali; J Feris; E Leibovitz; D J Burch; M R Jacobs
Journal:  Pediatr Infect Dis J       Date:  2000-02       Impact factor: 2.129

Review 8.  Moraxella catarrhalis: a review of an important human mucosal pathogen.

Authors:  R Karalus; A Campagnari
Journal:  Microbes Infect       Date:  2000-04       Impact factor: 2.700

9.  In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin.

Authors:  Catherine Clark; Bülent Bozdogan; Mihaela Peric; Bonifacio Dewasse; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

10.  Diversity of beta-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae.

Authors:  Henri Dabernat; Catherine Delmas; Martine Seguy; Roseline Pelissier; Genevieve Faucon; Safia Bennamani; Christophe Pasquier
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

View more
  12 in total

1.  Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria.

Authors:  Catherine Clark; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

Review 2.  Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

3.  Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.

Authors:  Cesar A Arias; Kavindra V Singh; Diana Panesso; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

4.  Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.

Authors:  David J Farrell; Robert K Flamm; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

5.  Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae.

Authors:  Todd A Davies; Malcolm G P Page; Wenchi Shang; Ted Andrew; Malgosia Kania; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

6.  Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.

Authors:  Gary J Noel; Richard S Strauss; Karen Amsler; Markus Heep; Rienk Pypstra; Joseph S Solomkin
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

7.  Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.

Authors:  Steven N Leonard; Chrissy M Cheung; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

8.  In vitro capability of faropenem to select for resistant mutants of Streptococcus pneumoniae and Haemophilus influenzae.

Authors:  Klaudia Kosowska-Shick; Catherine Clark; Kim Credito; Bonifacio Dewasse; Linda Beachel; Lois Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

9.  Resistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.

Authors:  April Barbour; Hartmut Derendorf
Journal:  Ther Clin Risk Manag       Date:  2010-10-05       Impact factor: 2.423

10.  Emerging agents to combat complicated and resistant infections: focus on ceftobiprole.

Authors:  César Bustos; Jose L Del Pozo
Journal:  Infect Drug Resist       Date:  2010-04-22       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.